Diabetes Mellitus/diagnosis/*drug therapy/epidemiology Dose-Response Relationship Drug Humans Hypoglycemic Agents/*adverse effects Linear Models Multivariate Analysis Odds Ratio Pioglitazone Risk Assessment Risk Factors Thiazolidinediones/*adverse effects Time Factors Urinary Bladder Neoplasms/*chemically induced/diagnosis/epidemiology

Humans *Lymph Node Excision Lymphatic Metastasis Muscle Smooth/pathology Neoplasm Invasiveness Prognosis Urinary Bladder Neoplasms/pathology/*surgery Cáncer vesical con infiltración de la muscular Linfadenectomía Lymph node anatomical territory Lymphadenectomy Muscle invasive bladder cancer Oncological value Territorios anatómicos ganglionares Valor oncológico

Animals Cattle Diet/*adverse effects *Evidence-Based Medicine Food Preserved/*adverse effects Humans Incidence Meat/*adverse effects Meat Products/*adverse effects Reproducibility of Results Risk Factors Sheep Domestic Sus scrofa Urinary Bladder Neoplasms/epidemiology/*etiology Bladder cancer Dose–response Meta-analysis Processed meat Red meat

Acetylation Arylamine N-Acetyltransferase/*genetics/metabolism Asian People/genetics Case-Control Studies China/epidemiology Genetic Association Studies Genetic Predisposition to Disease Humans Odds Ratio Phenotype *Polymorphism Single Nucleotide Risk Assessment Risk Factors Urinary Bladder Neoplasms/enzymology/ethnology/*genetics

Cation Transport Proteins/*genetics Glutathione Peroxidase/*genetics Humans Neoplasm Recurrence Local/genetics Polymorphism Genetic Survival Analysis Urinary Bladder Neoplasms/genetics/*pathology Glutathione Peroxidase GPX1 Nmibc Nramp1 d534n hGPX1 Pro168Leu meta-analysis recurrence

Asian People/genetics Female Humans Male Microtubule-Associated Proteins/*genetics *Polymorphism Single Nucleotide Urinary Bladder Neoplasms/ethnology/*genetics/pathology White People/genetics

Biomarkers Tumor/*urine Carcinoma Transitional Cell/pathology/*urine Gene Expression Regulation Neoplastic Humans Prognosis RNA Long Noncoding/*urine Urinary Bladder Neoplasms/pathology/*urine Bladder cancer biomarker diagnosis long non-coding RNA urothelial carcinoma–associated 1

Clinical Decision-Making Cystectomy/*methods Cytoreduction Surgical Procedures/methods Humans *Neoplasm Metastasis/pathology/therapy Practice Guidelines as Topic Treatment Outcome *Urinary Bladder Neoplasms/pathology/surgery Bladder cancer Lymph node dissection Lymph node metastasis Metastasectomy Metastatic bladder cancer Surgery interest including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg employment/affiliation grants or funding consultancies honoraria stock ownership or options expert testimony royalties or patents filed received or pending) are the following: None.

Antioxidants/*therapeutic use Databases Factual Dietary Supplements Humans Randomized Controlled Trials as Topic Risk Urinary Bladder Neoplasms/pathology/*prevention & control Vitamins/*therapeutic use beta Carotene/therapeutic use Antioxidant Bladder Cancer Meta-Analysis Randomized Controlled Trials Vitamin

Aged Catheterization Chemotherapy Adjuvant Feasibility Studies Female Humans *Laser Therapy Length of Stay Male Middle Aged Operative Time Postoperative Complications/etiology Time Factors Treatment Outcome Urinary Bladder Neoplasms/drug therapy/pathology/*radiotherapy/*surgery Bladder tumor Laser enucleation of bladder tumor Meta-analysis Transurethral resection of bladder tumor (TURBT)

Carcinoma Transitional Cell/pathology/*surgery Cystectomy/*methods Humans Kaplan-Meier Estimate Neoplasm Recurrence Local Risk Factors Urethra/*pathology Urinary Bladder/pathology/surgery Urinary Bladder Neoplasms/pathology/*surgery Bladder cancer Neobladder Radical cystectomy Urethral recurrence Urothelial carcinoma

Fluorodeoxyglucose F18 Humans Lymph Nodes/*diagnostic imaging/pathology Lymphatic Metastasis/diagnosis/*diagnostic imaging/pathology Neoplasm Staging/methods Positron Emission Tomography Computed Tomography/*methods ROC Curve Sensitivity and Specificity Urinary Bladder Neoplasms/*diagnostic imaging/pathology/surgery Bladder cancer F-18 fluorodeoxyglucose Lymph node Positron emission tomography/computed tomography Staging

Age Factors Aged Aged 80 and over Clinical Decision-Making *Cystectomy/adverse effects/mortality Disease-Free Survival Female Geriatric Assessment Humans Life Expectancy Male Middle Aged Neoplasm Invasiveness Odds Ratio Patient Selection Quality of Life Radiotherapy/adverse effects/mortality Risk Factors Time Factors Treatment Outcome Urinary Bladder Neoplasms/mortality/pathology/*therapy Complications Elderly Mibc Outcome

Adjuvants Immunologic/administration & dosage Administration Intravesical Antineoplastic Agents/therapeutic use BCG Vaccine/*administration & dosage Bayes Theorem Disease Progression Humans Immunotherapy/*methods Incidence Neoplasm Recurrence Local/drug therapy Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*drug therapy Intravesical bacillus Calmette–Guerin efficacy maintenance non-muscle-invasive bladder cancer side effects

Cystectomy/*methods Disease-Free Survival Humans Lymphatic Metastasis *Margins of Excision Neoplasm Recurrence Local Neoplasm Staging Prognosis Treatment Outcome Urinary Bladder Neoplasms/pathology/*surgery bladder cancer meta-analysis outcome radical cystectomy surgical margin status

Administration Intravesical Aged Aged 80 and over Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects BCG Vaccine/administration & dosage Bayes Theorem Deoxycytidine/administration & dosage/analogs & derivatives Disease Progression Epirubicin/administration & dosage Female Humans Isoniazid/administration & dosage Male Middle Aged Mitomycin/administration & dosage Neoplasm Invasiveness Neoplasm Recurrence Local Odds Ratio Randomized Controlled Trials as Topic Risk Factors Time Factors Treatment Outcome Urinary Bladder Neoplasms/*drug therapy/mortality/pathology Gemcitabine efficacy and safety intravesical therapy non-muscle invasive bladder cancer tumor progression tumor recurrence

Aged Aged 80 and over *Biomarkers Tumor Cluster Analysis Cohort Studies Female Gene Expression Profiling Humans Immunohistochemistry Male Middle Aged Mutation Neoplasm Invasiveness Neoplasm Staging Neoplasms Basal Cell/*diagnosis/genetics/*metabolism/mortality Prognosis Survival Analysis Tissue Array Analysis Urinary Bladder Neoplasms/*diagnosis/genetics/*metabolism/mortality Biomarker Bladder cancer

Antibiotics Antineoplastic/*therapeutic use BCG Vaccine/*therapeutic use Combined Modality Therapy Humans Mitomycin/*therapeutic use Urinary Bladder Neoplasms/*drug therapy bacillus Calmette-Guérin mitomycin C non-muscle-invasive bladder carcinoma recurrence rate meta-analysis.

Biomarkers Tumor/*genetics Epigenesis Genetic/*genetics Humans Methylation Mycobacterium bovis/*genetics Prognosis Urinary Bladder Neoplasms/*genetics/pathology/surgery

Cystectomy/*methods Feasibility Studies Humans Treatment Outcome Urethra Urinary Bladder Neoplasms/*surgery